The metabolic activation of mitotane may take place in the tumor and be dependent on either CYP11B1 or a non-steroidogenic CYP, and there is some evidence that the capability of the tumor to metabolize mitotane may predict response to treatment [11, 12]. This evidence concerns the gene PPIG and neoplasm.